Abstract
Oncogenic transformation of growth factors, growth factor receptors, transcription factors as well as important cellular proteins and their association with the principal tumor suppressor p53 may provide essential insights toward integrated therapy in breast cancer. In this review we discuss growth factor HER-2/neu receptor tyrosine kinase; FAK, non-receptor tyrosine kinase; TGF-β, and their roles in tumorigenesis in breast cell with respect to p53. VEGF is a powerful angiogenic factor and its expression is also regulated by p53. E3 ligases like MDM2 and cullin 7 are considered as oncoproteins and they interact differently with p53 in breast cells. Aberrant expression of these ligases is associated with tumorigenesis. The transcription factor cyclin E is involved in cell cycle progression while its activity is subjected to p53 regulation through p21. The necrosis factor NF-κB regulates p53 expression by binding to its promoter and modulates expression of anti-apoptotic protein survivin in breast cancer cell. Apoptosis by Bcl-2 family of protein is largely dependent upon the balance of pro-apoptotic and anti-apoptotic protein expression regulated by p53. In essence, the complexities of p53 interactions with various types of oncogene products require close exploration towards an integrated therapy against breast cancer.
Keywords: Anti-sense oligonucleotide, Bcl-2, breast cancer, epithelial to messenchymal transition (EMT), FAK, HER-2/neu, MDM2 and cullin 7, NF-κB, oncogene, p21, p53, reactive oxygen species (ROS), siRNA, survivin, TGF-β, tumor suppressor, VEGF.
Graphical Abstract
Current Cancer Therapy Reviews
Title:Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer
Volume: 11 Issue: 1
Author(s): Nabilah Ibnat and Ezharul Hoque Chowdhury
Affiliation:
Keywords: Anti-sense oligonucleotide, Bcl-2, breast cancer, epithelial to messenchymal transition (EMT), FAK, HER-2/neu, MDM2 and cullin 7, NF-κB, oncogene, p21, p53, reactive oxygen species (ROS), siRNA, survivin, TGF-β, tumor suppressor, VEGF.
Abstract: Oncogenic transformation of growth factors, growth factor receptors, transcription factors as well as important cellular proteins and their association with the principal tumor suppressor p53 may provide essential insights toward integrated therapy in breast cancer. In this review we discuss growth factor HER-2/neu receptor tyrosine kinase; FAK, non-receptor tyrosine kinase; TGF-β, and their roles in tumorigenesis in breast cell with respect to p53. VEGF is a powerful angiogenic factor and its expression is also regulated by p53. E3 ligases like MDM2 and cullin 7 are considered as oncoproteins and they interact differently with p53 in breast cells. Aberrant expression of these ligases is associated with tumorigenesis. The transcription factor cyclin E is involved in cell cycle progression while its activity is subjected to p53 regulation through p21. The necrosis factor NF-κB regulates p53 expression by binding to its promoter and modulates expression of anti-apoptotic protein survivin in breast cancer cell. Apoptosis by Bcl-2 family of protein is largely dependent upon the balance of pro-apoptotic and anti-apoptotic protein expression regulated by p53. In essence, the complexities of p53 interactions with various types of oncogene products require close exploration towards an integrated therapy against breast cancer.
Export Options
About this article
Cite this article as:
Ibnat Nabilah and Hoque Chowdhury Ezharul, Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/157339471101150709141340
DOI https://dx.doi.org/10.2174/157339471101150709141340 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Ethical Implications of Pharmacogenetics: Shaping the Future of the Field
Current Pharmacogenomics Recent Advance of Computational Approaches in Genomics and Proteomics
Current Bioinformatics Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry Synthesis of Fluorine-18-Labelled Choline (<sup>18</sup>F-Fluorocholine): Towards an Early and Accurate Management of Prostate Cancer in Malaysia
Current Medical Imaging Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Modification of Polyfluoro-Containing 3-(Ethoxycarbonyl)flavones by Biogenic Amines and Amino Acids
Current Organic Synthesis REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Muscarinic Activation Enhances the Anti-proliferative Effect of Paclitaxel in Murine Breast Tumor Cells
Anti-Cancer Agents in Medicinal Chemistry Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Current Drug Metabolism PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine